Gilead 4Q Revenues: $7.2 billion (-2%) 4Q Earnings: $376 million (earnings were $1.5 billion 4Q21)  FY Revenues: $27.3 billion (+11%) FY Earnings: $6.2 billion (earnings were $89 million FY21) Comments: Total product sales in the quarter decreased 2% to $7.2 billion due to decreased demand for Veklury (remdesivir), partially offset by favorable pricing dynamics in HIV. Total product sales excluding Veklury increased 8% to $5.8 billion for the quarter, primarily reflecting higher demand for ...